Vir Biotechnology (VIR) Goodwill & Intangibles (2018 - 2026)
Vir Biotechnology recorded quarterly Goodwill & Intangibles of $24.7 million in Q1 2026, little changed quarter-over-quarter from $24.8 million in Q4 2025, and down 1.18% year-over-year from $25.0 million in Q1 2025.
Vir Biotechnology's Goodwill & Intangibles history runs 9 years deep, the most recent figure standing at $24.7 million for Q1 2026.
- In Q1 2026, Goodwill & Intangibles fell 1.18% year-over-year to $24.7 million; the TTM figure through Mar 2026 stood at $24.7 million (down 1.18% YoY), while the FY2025 annual figure was $24.8 million, down 1.08% from the prior year.
- Goodwill & Intangibles came in at $24.7 million for Q1 2026 at Vir Biotechnology, roughly flat from $24.8 million in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $50.1 million in Q1 2022 to a low of $24.7 million in Q1 2026.
- A 5-year average of $37.3 million and a median of $39.4 million in 2024 frame the typical range for Goodwill & Intangibles.
- Across the five-year window, Goodwill & Intangibles dropped 1.05% in 2022 and tumbled 36.57% in 2024, its largest moves.
- Vir Biotechnology's Goodwill & Intangibles stood at $49.7 million in 2022, then retreated by 20.51% to $39.5 million in 2023, then plunged by 36.57% to $25.1 million in 2024, then dropped by 1.08% to $24.8 million in 2025, then dropped by 0.29% to $24.7 million in 2026.
- According to Business Quant data, Goodwill & Intangibles over the past three periods registered $24.7 million, $24.8 million, and $24.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.71 Mn |
| Dec 31, 2025 | 24.79 Mn |
| Sep 30, 2025 | 24.86 Mn |
| Jun 30, 2025 | 24.94 Mn |
| Mar 31, 2025 | 25.01 Mn |
| Dec 31, 2024 | 25.06 Mn |
| Sep 30, 2024 | 36.20 Mn |
| Jun 30, 2024 | 35.84 Mn |
| Mar 31, 2024 | 39.40 Mn |
| Dec 31, 2023 | 39.50 Mn |
| Sep 30, 2023 | 42.39 Mn |
| Jun 30, 2023 | 42.53 Mn |
| Mar 31, 2023 | 49.56 Mn |
| Dec 31, 2022 | 49.69 Mn |
| Sep 30, 2022 | 49.83 Mn |
| Jun 30, 2022 | 49.96 Mn |
| Mar 31, 2022 | 50.09 Mn |
| Dec 31, 2021 | 50.22 Mn |
| Sep 30, 2021 | 50.36 Mn |
| Jun 30, 2021 | 50.49 Mn |
| Mar 31, 2021 | 50.62 Mn |
| Dec 31, 2020 | 50.76 Mn |
| Sep 30, 2020 | 50.84 Mn |
| Jun 30, 2020 | 52.02 Mn |
| Mar 31, 2020 | 52.33 Mn |
| Dec 31, 2019 | 52.63 Mn |
| Sep 30, 2019 | 52.94 Mn |
| Dec 31, 2018 | 53.85 Mn |